12 April 2021 | News
Centre takes various steps to ensure easy access of Remdesivir to Patients and Hospitals
Image credit- shutterstock.com
India is witnessing a recent surge in COVID-19 cases. This has led to a sudden spike in demand for Injection Remdesivir used in treatment of COVID-19 patients. There is a potential of further increase in this demand in the coming days.
Seven Indian companies are producing Injection Remdesivir under voluntary licensing agreement with Gilead Sciences, USA. They have an installed capacity of about 38.80 lakh units per month.
In light of the above, Government of India has prohibited the exports of Injection Remdesivir and Remdesivir Active Pharmaceutical Ingredients (API) till the situation improves.
In addition, Government of India has taken the following steps to ensure easy access of hospital and patients to Remdesivir: